Management of Skin and Soft Tissue Abscesses in Pediatric Patients After Incision and Drainage

This study has been completed.
Sponsor:
Information provided by:
Baylor College of Medicine
ClinicalTrials.gov Identifier:
NCT00691600
First received: December 28, 2007
Last updated: December 2, 2010
Last verified: December 2010
  Purpose

The purpose of this study is to compare successful rates of cure of abscesses less than 5 cm with antibiotic versus non-antibiotic treatment after incision and drainage. We will also compare successful rates of cure and time to healing with IV antibiotics and 23-hour observation unit stay versus hospitalization with IV antibiotics for abscesses greater than 5 cm but less than 10 cm in pediatric patients.


Condition Intervention Phase
Abscess
Drug: oral trimethoprim/sulfamethoxazole
Drug: Placebo
Other: Observational Unit Short Stay
Other: Hospitalization
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Single Group Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Phase 3 Study Comparing Bactrim to Placebo in the Management of Abscesses < 5cm and 23 hr Observation Unit to Inpatient Treatment in the Management of Abscesses 5-10cm in the Pediatric Population.

Resource links provided by NLM:


Further study details as provided by Baylor College of Medicine:

Primary Outcome Measures:
  • Proportion of patients having abscess resolution to those that do not for each of the treatment modalities employed. For the < 5 cm arm, compare the proportions of patients with successful outcomes between the placebo and TMP/SMX groups. [ Time Frame: 3yrs ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • The 5 - 10 cm arm, will compare the proportions of patients with successful outcomes between the 23-hour observation and hospitalization groups. [ Time Frame: 3yrs ] [ Designated as safety issue: No ]

Estimated Enrollment: 472
Study Start Date: December 2007
Study Completion Date: April 2010
Primary Completion Date: April 2010 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Placebo Comparator: TMP/SMX vs Placebo
subjects with abscesses less than 5cm will be randomized to either study med or placebo
Drug: oral trimethoprim/sulfamethoxazole
80 mg caps or 8 mg/ml suspension every 12 hours for 10 days
Other Name: Bactrim
Drug: Placebo
Placebo caps or suspension every 12 hours for 10 days
Hospitalization vs. 23 HR OBS Unit
Patients with abscesses 5-10cm will be randomized to either inpatient stay or 23 hour short stay in the observation unit.
Other: Observational Unit Short Stay
Patients with abscesses greater that 5cm to 10cm randomized to Observational Short Stay unit for up to 23 hrs.
Other: Hospitalization
Patients with abscesses 5-10cm may be randomized to inpatient treatment

  Eligibility

Ages Eligible for Study:   90 Days to 18 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Fluctuant abscess on trunk, scalp, extremities and axilla.

Exclusion Criteria:

  • Multiple abscesses
  • Abscesses greater than 10 cm
  • Abscesses located on the hands, face, and perineum
  • Bite wounds
  • Immunocompromised patients (including diabetes, sickle cell, chronic steroid therapy, etc.)
  • Previously failed 48 hours or greater therapy on any antibiotic regimen
  • Abscess less than 5 cm AND patient has (for exclusion criteria 7 - 10):
  • Drug allergy to TMP/SMX
  • Fever greater than or equal to 102.2 degrees F in last 24 hours
  • Systemic symptoms on presentation - i.e., nausea, vomiting, diaphoresis, etc. \
  • Signs/symptoms of another infection or illness - i.e., influenza, croup, etc. Abscess 5 - 10 cm AND patient has (for exclusion criterion 11): \
  • Drug allergy to both Clindamycin AND Vancomycin
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00691600

Locations
United States, Texas
Texas Children's Hospital
Houston, Texas, United States, 77030
Sponsors and Collaborators
Baylor College of Medicine
  More Information

No publications provided

Responsible Party: Charles Macias, MD, MPH, Baylor College of Medicine
ClinicalTrials.gov Identifier: NCT00691600     History of Changes
Other Study ID Numbers: H-18758
Study First Received: December 28, 2007
Last Updated: December 2, 2010
Health Authority: United States: Institutional Review Board

Keywords provided by Baylor College of Medicine:
abscess
Abscesses in the pediatric emergency population

Additional relevant MeSH terms:
Abscess
Suppuration
Infection
Inflammation
Pathologic Processes
Trimethoprim
Sulfamethoxazole
Anti-Infective Agents, Urinary
Anti-Infective Agents
Therapeutic Uses
Pharmacologic Actions
Renal Agents
Antimalarials
Antiprotozoal Agents
Antiparasitic Agents
Folic Acid Antagonists
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action

ClinicalTrials.gov processed this record on September 30, 2014